Parameters Arg/Arg n (%) Arg/Pro n (%) Pro/Pro n (%) Arg allele Pro allele Chi Sq. df p-value
Cases(100) 33(33) 50(50) 17(17) 0.58 0.42 18.06 2 0.0001
Contros(100) 62(62) 32(32) 06(6) 0.78 0.22      
Age                
40 years 8(25) 17(53.1) 7(21.8) 0.52 0.48 1.66 2 0.43
> 40 years 25(36.7) 33(48.5) 10(14.7) 0.61 0.39      
Stage                
I 3(33.3) 4(44.4) 2(22.2) 0.56 0.44 9.5 6 0.14
II 3(30.0) 4(40.0) 3(30.0) 0.5 0.5      
III 26(37.1) 32(45.7) 12(17.1) 0.6 0.4      
IV 1(9.09) 10(90.9) -- 0.55 0.45      
Histopathology                
Mucinous 16(35.5) 21(46.6) 8(17.7) 0.59 0.41 5.89 8 0.65
Serous 15(33.3) 25(55.5) 5(11.1) 0.61 0.39      
Endometroid 1(33.3) 1(33.3) 1(33.3) 0.5 0.5      
Clear Cell -- 1(50) 1(50) 0.25 0.75      
Mixed 1(20.0) 2(40.0) 2(40.0) 0.4 0.6      
Grade                
Well differentiated 5(35.7) 8(57.1) 1(7.1) 0.64 0.36 3.4 4 0.47
Moderately differentiated 19(28.7) 36(54.5) 11(16.6) 0.56 0.44      
Poorly differentiated 8(40.0) 7(35.0) 5(25.0) 0.57 0.43      
Table 4: Association of p53 gene polymorphism in EOC patients with their clinicopathological features.